The last year has been eye-opening. Among its many lessons, it exposed the fragility of central labs’ supply chains – built to manage increasing levels of complexity, but based on an assumption of stability.

As the impact of COVID-19 on clinical supply chains begins to decrease, we have an opportunity. We can take the lessons we learned during the past year and use them to optimize central lab logistics.

Implementing the three strategies presented here will equip central labs with the tools to run better trials and better grow their businesses far into the future – as well as mitigate risk.